Tirzepitide is known under the brand name Mounjaro Dual GLP agonist with better glycemic control and more weight loss than Ozempic which is a single GLP agonist. Weight loss indication is I believe for BMI higher than 30. My understanding is it is indicated for HF and being studied in other CV. It’s not for everyone and I feel that Vascepa has its place and doesn’t need a huge market share to be successful.
Market Data 
Markets 
AI
